Ilofotase alfa

DRUG3 trials

Sponsors

AM-Pharma B.V., AM-Pharma

Conditions

HypophosphatasiaOpen Heart SurgeryRisk for renal damage following open heart surgery

Phase 1

Open-Label Pilot Trial to Evaluate the Effects of Ilofotase Alfa on Biomarkers in Adult Patients with Hypophosphatasia

CompletedCTIS2023-503186-35-00

AM-Pharma B.V.Hypophosphatasia

Start: 2023-05-03End: 2023-07-12Target: 12Updated: 2023-05-09

Phase 2

Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ilofotase Alfa in Patients at Risk for Renal Damage Following Open Heart Surgery.

CompletedCTIS2023-505859-45-00

AM-Pharma B.V.Risk for renal damage following open heart surgery

Start: 2023-12-19End: 2025-12-03Target: 185Updated: 2025-09-25

Ilofotase Alfa for Prevention of Renal Damage After Cardiac Surgery

CompletedNCT06168799

AM-PharmaOpen Heart Surgery

Start: 2023-12-19End: 2025-12-03Updated: 2025-12-15

Related Papers

Study protocol for a multicentre randomised, double-blinded placebo-controlled phase 2 trial to evaluate safety and efficacy of ilofotase alfa in patients at risk for kidney injury following open heart surgery (Preprint)

2026-05-13